CAJ | 학술논문

建立了一种简便、灵敏的氯甲酸芴甲酯(FMOC-Cl)柱前衍生反相高效液相色谱-荧光检测血浆中奈替米星的新方法,同时研究了其药代动力学.对色谱条件进行了优化,采用ZORBAX Eclipse XDB-C_8柱(150 mm×4.6 mm,5 μm),流动相为乙腈-水(体积比为85∶15),流速为1.0 mL/min,荧光检测激发波长为265 nm,发射波长为315 nm,得到奈替米星的平均加标回收率为96.62% ～100.84%(n=3),对奈替米星检测的线性范围为0.045～8.88 mg/L,相关系数为 0.999 3,方法的日内与日间精密度分别低于3%与3.5%,最低检出限(S/N=3)与定量限(以3倍检出限计)分别为0.01和0.03 mg/L.方法简便、快速、灵敏,样品用量少(30 μL奈替米星血浆溶液已能满足该药含量的测定以及药物代谢的研究),为大鼠体内奈替米星的药代动力学研究提供了可靠的分析手段.
건립료일충간편、령민적록갑산물갑지(FMOC-Cl)주전연생반상고효액상색보-형광검측혈장중내체미성적신방법,동시연구료기약대동역학.대색보조건진행료우화,채용ZORBAX Eclipse XDB-C_8주(150 mm×4.6 mm,5 μm),류동상위을정-수(체적비위85∶15),류속위1.0 mL/min,형광검측격발파장위265 nm,발사파장위315 nm,득도내체미성적평균가표회수솔위96.62% ～100.84%(n=3),대내체미성검측적선성범위위0.045～8.88 mg/L,상관계수위 0.999 3,방법적일내여일간정밀도분별저우3%여3.5%,최저검출한(S/N=3)여정량한(이3배검출한계)분별위0.01화0.03 mg/L.방법간편、쾌속、령민,양품용량소(30 μL내체미성혈장용액이능만족해약함량적측정이급약물대사적연구),위대서체내내체미성적약대동역학연구제공료가고적분석수단.
A new, simple and sensitive method based on pre-column derivatization by reversed-phase high performance liquid chromatography (HPLC) is described for the separation and quantification of netilmicin in plasma, using 9-fluorenylmethyl chloroformate (FMOC-Cl) as the derivatization reagent. Its pharacokinetics is also presented. The derivatization modes and chromatographic conditions were optimized. The separation was performed on an Agilent ZOR-BAX Eclipse XDB-C_8 column (150 mm ×4. 6 mm, 5 μm) with a mixture of water-acetonitile (15:85, v/v) as mobile phase and the flow rate was 1.0 mL/min. The excitation wavelength was 265 nm and the emission wavelength was 315 nm. The linear range was 0. 045-8. 88 mg/L and the correlation coefficient (r) was 0. 999 3. The limit of detection (LOD) (S/N = 3) was about 0.01 mg/L, and the limit of quantification was 0.03 mg/L (3LOD) for netilmicin. The relative standard deviation was less than 3% for intra-day assay (n =5) and 3. 5% for inter-day assay (n = 5) and the relative recovery was in the range of 96. 62% - 100. 84% (n = 3). The plasma volume of 30 μL was sufficient for the determination of netilmicin. The method provides a reliable bioanalytical methodology to carry out netilmicin pharmacokinetics in rat plasma.